AHA, others file amicus briefs opposing major drug companies’ 340B rebate models
The AHA this week filed a number of friend-of-the-court briefs in cases before the U.S. District Court for the District of Columbia, urging the court to uphold the Health Resources and Services Administration’s decision to reject drug companies’ proposed 340B rebate models in separate lawsuits brought by a number of drug companies to bar the agency from doing so.
The AHA filed the following friend-of-the-court briefs:
- March 6 brief in case brought by Sanofi.
- March 5 brief in case brought by Kalderos.
- March 4 brief in case brought by Eli Lilly, Bristol Meyers Squibb and Novartis.
- Feb. 28 brief in case brought by Johnson & Johnson.
Others joining the AHA in the friend-of-the-court briefs were the Children’s Hospital Association, the Association of American Medical Colleges and America’s Essential Hospitals.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services has released a fact sheet and FAQs on the 340B Part D claims data repository that will go live Oct. 1. Data…
Headline
The AHA Aug. 26 urged the Centers for Medicare & Medicaid Services not to finalize two proposals in the calendar year 2027 outpatient prospective payment…
Headline
The AHA Aug. 25 submitted comments to Sen. Bill Cassidy, R-La., on the 340B Drug Pricing Integrity and Affordability for Patients Act (340B for Patients Act),…
Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …